Rasagiline is an irreversible monoamine oxidase-B inhibitor that is used as a monotherapy or as an

adjunct therapy to treat symptoms in early Parkinson's disease. Aspro Nicholas invented the racemic
form of the drug in the early 1970s. Rasagiline is used to treat Parkinson's disease symptoms alone or in
combination with other medications (such as levodopa/carbidopa). It can help with symptoms like
shakiness, stiffness, and difficulty moving. It can also assist in reducing the amount of "off" time (periods
of slow movement or stiffness). Rasagiline is an MAO inhibitor, which is a type of medication. It works by
raising the concentrations of certain natural substances in the brain (such as dopamine, norepinephrine,
serotonin). Parkinson's disease is believed to be caused by a lack of dopamine in the brain.
As directed by your doctor, take this medication by mouth, with or without food, once daily.
The dosage is determined by the medical condition, response to treatment, and any other medications
you are taking. Inform your doctor and pharmacist about all of the products you use (including
prescription drugs, nonprescription drugs, and herbal products). Do not increase your dose or take it
more frequently than recommended. Your condition will not improve any faster, and your chances of
experiencing side effects will increase.
it has many side affects such as :

 mild headache

 joint or neck pain

 heartburn

 nausea

 vomiting

 stomach pain

 constipation

 diarrhea

 loss of appetite

 weight loss

 flu-like symptoms

 fever

 sweating

 red, swollen, and/or itchy eyes

 dry mouth

 swollen gums
  unsteadiness, wobbliness, or lack of coordination

 involuntary, repeated body movements

 lack of energy

 sleepiness

 abnormal dreams

 depression

 pain, burning, numbness, or tingling in the hands or feet

 rash

 bruising or purple discoloration on skin

Parkinson's disease is characterized by the death of dopamine-producing cells, which are

neurotransmitters. Rasagiline inhibits dopamine breakdown by binding irreversibly to MAO-B. As a
result, dopamine is more readily available, partially compensating for the lower levels produced in
Parkinson's patients' brains. Selegiline was the first MAO-B inhibitor that was selective. In vivo, it is
partially metabolized to levomethamphetamine (l-methamphetamine), one of two enantiomers of
methamphetamine. While these metabolites may contribute to selegiline's ability to inhibit dopamine
and norepinephrine reuptake, they have also been linked to orthostatic hypotension and hallucinations
in some people.

This drug has a completely unique compound of C12H13N it has a covalent bond that makes all of the
detail percentage electron a good way to grow to be greater strong and feature a complete outer shell
of electron. in this compound there are 12 carbons 13 hydrogen 1 nitrogen and it has a benzene ring
with a 3 double bonds and a 2 carbons connected to each other through a triple bond and a nitrogen
connected to a carbon with a single bond . this makes the bonds withinside the factors more potent as it
incorporates triple bonds which makes it very tough to interrupt the bond and it might lower the gap
among electrons and protons and growth the appeal forces of the compound which would`ve made it
tougher to be damaged so the maximum right manner to ingest this compound withinside the frame is
through tablet due to the fact the hydrochloric acid withinside the frame will digest and destroy down
the compound and it's miles similarly damaged down into easy additives through the liver via enzymes .
and due to the bond that this compound possesses it'd be premier to be ingested as pills due to the fact
they're the toughest kind of bond but liquid from also can labored however it'd be much less powerful
furthermore direct dosses via a needle will be the least affective shape due to the fact the bonds among
the atoms is simply too strong.
Mla citation :
“Rasagiline.” National Center for Biotechnology Information. PubChem Compound
Database, U.S. National Library of Medicine,
https://pubchem.ncbi.nlm.nih.gov/compound/Rasagiline.
“Rasagiline.” Wikipedia, Wikimedia Foundation, 23 Mar. 2022,
https://en.wikipedia.org/wiki/Rasagiline.
“Rasagiline: Medlineplus Drug Information.” MedlinePlus, U.S. National Library of
Medicine, https://medlineplus.gov/druginfo/meds/a606017.html.
“Rasagiline Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing.” WebMD,
WebMD, https://www.webmd.com/drugs/2/drug-144380/rasagiline-oral/details.
“Rasagiline (Azilect): Basics, Side Effects & Reviews.” GoodRx,
https://www.goodrx.com/rasagiline/what-is.